99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent

Mirković, Marija; Radović, Magdalena; Stanković, D.; Milanović, Zorana; Janković, Drina; Matović, Milovan D.; Jeremic, Marija; Antić, Bratislav; Vranješ-Đurić, Sanja

doi:10.1016/j.msec.2019.04.034

Cited by 29 publications

(16 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, no radioactive signal was found in the thyroid, suggesting that the complexation of 99m Tc and HA-CHEMS-Cur-TPGS is stable in vivo, the conclusion according to that free 99m Tc can be oxidized to 99m TcO 4 − and accumulate in the thyroid. 50,51 Quantitative analysis of microSPECT images showed that the maximum radioactivity intensity of tumor tissue was 4.85±0.24%ID/g at 4 h post-injection but was less than 1%ID/g in the control group ( Figure 5C). Notably, there was more than 3%ID/g of the radioactivity retained in tumor tissue at 8 h postinjection.…”

Section: In Vivo Imaging and Pharmacokineticsmentioning

confidence: 99%

99mTc Radiolabeled HA/TPGS-Based Curcumin-Loaded Nanoparticle for Breast Cancer Synergistic Theranostics: Design, in vitro and in vivo Evaluation

Huang¹,

Chen²,

Zhang³

et al. 2020

IJN

View full text Add to dashboard Cite

Background: Emerging cancer therapy requires highly sensitive diagnosis in combination with cancer-targeting therapy. In this study, a self-assembled pH-sensitive curcumin (Cur)loaded nanoparticle of 99m Tc radiolabeled hyaluronan-cholesteryl hemisuccinate conjugates (HA-CHEMS) and D-a-tocopheryl polyethylene glycol succinate (TPGS) was prepared for breast cancer synergistic theranostics. Materials and Methods: The synthesized amphiphilic HA-CHEMS conjugates and TPGS self-assembled into Cur-loaded nanoparticles (HA-CHEMS-Cur-TPGS NPs) in an aqueous environment. The physicochemical properties of HA-CHEMS-Cur-TPGS NPs were characterized by transmission electron microscopy (TEM) and dynamic lighter scattering (DLS). The in vitro cytotoxicity of HA-CHEMS-Cur-TPGS NPs against breast cancer cells was evaluated by using the methyl thiazolyl tetrazolium (MTT) assay. Moreover, the in vivo animal experiments of HA-CHEMS-Cur-TPGS NPs including SPECT/CT imaging biodistribution and antitumor efficiency were investigated in 4T1 tumor-bearing BALB/c mice; furthermore, pharmacokinetics were investigated in healthy mice. Results: HA-CHEMS-Cur-TPGS NPs exhibited high curcumin loading, uniform particle size distribution, and excellent stability in vitro. In the cytotoxicity assay, HA-CHEMS-Cur-TPGS NPs showed remarkably higher cytotoxicity to 4T1 cells with an IC50 value at 38 μg/ mL, compared with free curcumin (77 μg/mL). Moreover, HA-CHEMS-Cur-TPGS NPs could be effectively and stably radiolabeled with 99m Tc. The SPECT images showed that 99m Tc-HA-CHEMS-Cur-TPGS NPs could target the 4T1 tumor up to 4.85±0.24%ID/g at 4 h post-injection in BALB/c mice. More importantly, the in vivo antitumor efficacy studies showed that HA-CHEMS-Cur-TPGS NPs greatly inhibited the tumor growth without resulting in obvious toxicities to major organs. Conclusion: The results indicated that HA-CHEMS-Cur-TPGS NPs with stable 99m Tc labeling and high curcumin-loading capacity hold great potential for breast cancer synergistic theranostics.

show abstract

Section: In Vivo Imaging and Pharmacokineticsmentioning

confidence: 99%

99mTc Radiolabeled HA/TPGS-Based Curcumin-Loaded Nanoparticle for Breast Cancer Synergistic Theranostics: Design, in vitro and in vivo Evaluation

Huang¹,

Chen²,

Zhang³

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…Stannous chloride also facilitated radiolabeling reactions. 22,23 In this study, the effect of stannous chloride on the radiolabeling process was examined, and ideal stannous chloride amount was found to be 500 μg. The radiochemical purity of [ 99m Tc]-TcIMT with 500 μg/mL stannous chloride solution was over 90% and did not change significantly for 6 h at room temperature (p > 0.05) (Figure 6).…”

Section: ■ Resultsmentioning

confidence: 98%

Applying Quality by Design Principles in the Development and Preparation of a New Radiopharmaceutical: Technetium-99m-Imatinib Mesylate

et al. 2020

View full text Add to dashboard Cite

“…Mirković et al. have been used 99mTc‐Fe 3 O 4 ‐HEDP‐MNPS nanoprobe in ex‐vivo biodistribution studies and they showed significant uptake in the liver and spleen in healthy Wistar rats after intravenous administration [ 114 ]. Moreover, the results of scintigraphy studies indicated high in vivo stability.…”

Section: Theranostic Nanoparticlesmentioning

confidence: 99%

Recent nanotheranostics applications for cancer therapy and diagnosis: A review

Aminolroayaei

Shahbazi‐Gahrouei

Shahbazi-Gahrouei

et al. 2021

IET Nanobiotechnology

View full text Add to dashboard Cite

Nanotheranostics has attracted much attention due to its widespread application in molecular imaging and cancer therapy. Molecular imaging using nanoparticles has attracted special attention in the diagnosis of cancer at early stages. With the progress made in nanotheranostics, studying drug release, accumulation in the target tissue, biodistribution, and treatment effectiveness are other important factors. However, according to the studies conducted in this regard, each nanoparticle has some advantages and limitations that should be examined and then used in clinical applications. The main goal of this review is to explore the recent advancements in nanotheranostics for cancer therapy and diagnosis. Then, it is attempted to present recent studies on nanotheranostics used as a contrast agent in various imaging modalities and a platform for cancer therapy.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent

Cited by 29 publications

References 44 publications

<p><sup>99m</sup>Tc Radiolabeled HA/TPGS-Based Curcumin-Loaded Nanoparticle for Breast Cancer Synergistic Theranostics: Design, in vitro and in vivo Evaluation</p>

<p><sup>99m</sup>Tc Radiolabeled HA/TPGS-Based Curcumin-Loaded Nanoparticle for Breast Cancer Synergistic Theranostics: Design, in vitro and in vivo Evaluation</p>

Applying Quality by Design Principles in the Development and Preparation of a New Radiopharmaceutical: Technetium-99m-Imatinib Mesylate

Recent nanotheranostics applications for cancer therapy and diagnosis: A review

Contact Info

Product

Resources

About